LONG-TERM DEBT (Tables)

6 Months Ended

Jan. 30, 2021

Debt Disclosure [Abstract]

Schedule of Debt

The Company’s long-term debt consisted of the following:

(in thousands)	Average Interest Rate at January 30, 2021	Fiscal Maturity Year	January 30, 2021		August 1, 2020
Term Loan Facility	4.37%	2026	$	1,015,000	$	1,773,000
ABL Credit Facility	1.52%	2024	885,000		756,712
Senior Notes	6.75%	2029	500,000		—
Other secured loans	5.18%	2024-2025	42,966		49,268
Debt issuance costs, net			(37,128)		(45,846)
Original issue discount on debt			(18,597)		(35,508)
Long-term debt, including current portion			2,387,241		2,497,626
Less: current portion of long-term debt			(12,991)		(70,632)
Long-term debt			$	2,374,250	$	2,426,994

Schedule of Line of Credit Facilities

The assets included in the Condensed Consolidated Balance Sheets securing the outstanding obligations under the ABL Credit Facility on a first-priority basis, and the unused credit and fees under the ABL Credit Facility, were as follows:

Assets securing the ABL Credit Facility (in thousands)(1):	January 30, 2021		August 1, 2020
Certain inventory assets included in Inventories, net and Current assets of discontinued operations	$	2,261,209	$	2,270,892
Certain receivables included in Accounts receivable, net and Current assets of discontinued operations	$	1,104,388	$	1,077,682

(1)The ABL Credit Facility is also secured by all of the Company’s pharmacy scripts, which are included in Intangibles, net in the Condensed Consolidated Balance Sheets as of January 30, 2021 and August 1, 2020.

Unused credit and fees under the ABL Credit Facility (in thousands, except percentages):	January 30, 2021
Outstanding letters of credit	$	95,789
Letter of credit fees	1.375		%
Unused credit	$	1,117,774
Unused facility fees	0.25		%